The Conversation (0)
Adamas Announces Publication of ADS-5102 Phase 2 Clinical Trial Results in Multiple Sclerosis Journal
Feb. 02, 2018 08:38AM PST
Pharmaceutical Investing
Adamas Pharmaceuticals (Nasdaq:ADMS) announced that results of its Phase 2 proof-of-concept clinical trial of ADS-5102 (amantadine) extended release capsules in multiple sclerosis (MS) patients with walking impairment were published online in Multiple Sclerosis Journal. As quoted in the press release: “In this proof-of-concept study, a greater proportion of ADS-5102 patients had at least a 20 percent …
Adamas Pharmaceuticals (Nasdaq:ADMS) announced that results of its Phase 2 proof-of-concept clinical trial of ADS-5102 (amantadine) extended release capsules in multiple sclerosis (MS) patients with walking impairment were published online in Multiple Sclerosis Journal.
As quoted in the press release:
“In this proof-of-concept study, a greater proportion of ADS-5102 patients had at least a 20 percent improvement in walking speed compared with the placebo group,” stated Jeffrey A. Cohen, M.D., Mellen Center for Multiple Sclerosis Treatment and Research, Neurological Institute, Cleveland Clinic, and a paid consultant for Adamas.
